Pay in 4 interest-free payments of $5.65 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
As clinicians increasingly encounter patients with IBD as well as obesity, diabetes, or metabolic liver disease, there is a clear need to synthesize what is known about safety, metabolic effects, and IBD-specific outcomes to support evidence-informed clinical decision-making, explains senior investigator and study author Jolle St-Pierre, MD, PhD, FRCPC, a clinical assistant professor in the Division of Gastroenterology and Hepatology at the University of Calgary, Canada, in an email to Gastro Today
Medical Encyclopedia (republished by Lima Memorial Health System)
The practical impact is likely minimal at the subclinical fluid shifts seen with standard ipamorelin dosing (200 to 300 mcg subcutaneously)
Open Access Emerg
20 May 2009
